- Home
- NTIP vs DXR Comparison
NTIP vs DXR Comparison
Compare NTIP & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- DXR
- Stock Information
- Founded
- NTIP 1990
- DXR 1970
- Country
- NTIP United States
- DXR United States
- Employees
- NTIP N/A
- DXR N/A
- Industry
- NTIP Multi-Sector Companies
- DXR Medical/Dental Instruments
- Sector
- NTIP Miscellaneous
- DXR Health Care
- Exchange
- NTIP Nasdaq
- DXR Nasdaq
- Market Cap
- NTIP 31.9M
- DXR 36.4M
- IPO Year
- NTIP 1998
- DXR N/A
- Fundamental
- Price
- NTIP $1.21
- DXR $7.75
- Analyst Decision
- NTIP
- DXR Strong Buy
- Analyst Count
- NTIP 0
- DXR 1
- Target Price
- NTIP N/A
- DXR $25.00
- AVG Volume (30 Days)
- NTIP 11.4K
- DXR 4.8K
- Earning Date
- NTIP 05-16-2025
- DXR 01-01-0001
- Dividend Yield
- NTIP 8.03%
- DXR N/A
- EPS Growth
- NTIP N/A
- DXR 86.16
- EPS
- NTIP N/A
- DXR 0.11
- Revenue
- NTIP $100,000.00
- DXR $119,714.00
- Revenue This Year
- NTIP N/A
- DXR N/A
- Revenue Next Year
- NTIP N/A
- DXR N/A
- P/E Ratio
- NTIP N/A
- DXR $70.84
- Revenue Growth
- NTIP N/A
- DXR N/A
- 52 Week Low
- NTIP $1.17
- DXR $6.55
- 52 Week High
- NTIP $2.00
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- NTIP 41.74
- DXR 51.69
- Support Level
- NTIP $1.17
- DXR $7.13
- Resistance Level
- NTIP $1.28
- DXR $7.74
- Average True Range (ATR)
- NTIP 0.04
- DXR 0.33
- MACD
- NTIP 0.00
- DXR 0.02
- Stochastic Oscillator
- NTIP 33.33
- DXR 89.04
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.